N.P. Koper

1.4k total citations · 1 hit paper
20 papers, 1.0k citations indexed

About

N.P. Koper is a scholar working on Reproductive Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, N.P. Koper has authored 20 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Reproductive Medicine, 8 papers in Oncology and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in N.P. Koper's work include Ovarian cancer diagnosis and treatment (7 papers), HER2/EGFR in Cancer Research (6 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). N.P. Koper is often cited by papers focused on Ovarian cancer diagnosis and treatment (7 papers), HER2/EGFR in Cancer Research (6 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). N.P. Koper collaborates with scholars based in Netherlands, United States and United Kingdom. N.P. Koper's co-authors include Philippe Aftimos, Lambertus A. Kiemeney, Udai Banerji, Ellen C.M. Mommers, Valentina Boni, Víctor Moreno, Elisabeth G.E. de Vries, Jill J.J. Geenen, Cristina Saura and Fiona Thistlethwaite and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Annals of Oncology.

In The Last Decade

N.P. Koper

20 papers receiving 997 citations

Hit Papers

Trastuzumab duocarmazine in locally advanced and metastat... 2019 2026 2021 2023 2019 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
    2019 400 citations Udai Banerji, Carla M.L. van Herpen et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
N.P. Koper Netherlands 12 583 351 231 176 148 20 1.0k
Soon‐Beom Kang South Korea 24 354 0.6× 161 0.5× 692 3.0× 188 1.1× 75 0.5× 64 1.5k
Hamdy A. Azim Egypt 19 766 1.3× 141 0.4× 51 0.2× 352 2.0× 127 0.9× 66 1.1k
Sileny Han Belgium 23 1.1k 1.9× 64 0.2× 288 1.2× 139 0.8× 167 1.1× 73 1.5k
Catherine Shannon Australia 20 704 1.2× 43 0.1× 171 0.7× 286 1.6× 70 0.5× 48 1.2k
J. F. Pringle Canada 18 480 0.8× 154 0.4× 355 1.5× 310 1.8× 60 0.4× 22 1.3k
Jørn Andersen Denmark 20 461 0.8× 103 0.3× 425 1.8× 107 0.6× 81 0.5× 36 1.0k
Noriko Seki Japan 17 332 0.6× 139 0.4× 266 1.2× 66 0.4× 29 0.2× 39 892
Josep R. Germà Spain 17 524 0.9× 149 0.4× 56 0.2× 330 1.9× 36 0.2× 29 1.1k
Robert D. Legare United States 14 449 0.8× 60 0.2× 90 0.4× 68 0.4× 89 0.6× 35 822
Jeffrey Schneider United States 15 592 1.0× 41 0.1× 62 0.3× 160 0.9× 58 0.4× 40 882

Countries citing papers authored by N.P. Koper

Since Specialization
Citations

This map shows the geographic impact of N.P. Koper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N.P. Koper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N.P. Koper more than expected).

Fields of papers citing papers by N.P. Koper

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by N.P. Koper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N.P. Koper. The network helps show where N.P. Koper may publish in the future.

Co-authorship network of co-authors of N.P. Koper

This figure shows the co-authorship network connecting the top 25 collaborators of N.P. Koper. A scholar is included among the top collaborators of N.P. Koper based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with N.P. Koper. N.P. Koper is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Aftimos, Philippe, Nicholas C. Turner, Joyce O’Shaughnessy, et al.. (2023). 386MO Trastuzumab duocarmazine versus physician's choice therapy in pre-treated HER2-positive metastatic breast cancer: Final results of the phase III TULIP trial. Annals of Oncology. 34. S340–S341. 16 indexed citations
2.
3.
Banerji, Udai, Carla M.L. van Herpen, Cristina Saura, et al.. (2019). Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. The Lancet Oncology. 20(8). 1124–1135. 400 indexed citations breakdown →
4.
Koper, N.P., et al.. (2019). Comparison of Copaxone® and Synthon's therapeutically equivalent glatiramer acetate.. PubMed. 74(8). 449–461. 1 indexed citations
5.
Saura, Cristina, Fiona Thistlethwaite, Udai Banerji, et al.. (2018). A phase I expansion cohorts study of SYD985 in heavily pretreated patients with HER2-positive or HER2-low metastatic breast cancer.. Journal of Clinical Oncology. 36(15_suppl). 1014–1014. 53 indexed citations
6.
Selmaj, Krzysztof, Frederik Barkhof, Christian Wolf, et al.. (2017). Switching from branded to generic glatiramer acetate: 15-month GATE trial extension results. Multiple Sclerosis Journal. 23(14). 1909–1917. 19 indexed citations
7.
Cohen, Jeffrey A., Anna N. Belova, Krzysztof Selmaj, et al.. (2015). Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis. JAMA Neurology. 72(12). 1433–1433. 59 indexed citations
8.
Herpen, Carla M. van, Udai Banerji, Ellen C.M. Mommers, et al.. (2015). 333 Phase I dose-escalation trial with the DNA-alkylating anti-HER2 antibody-drug conjugate SYD985. European Journal of Cancer. 51. S65–S65. 10 indexed citations
9.
10.
11.
Aben, Katja K.H., Jacqueline Cloos, N.P. Koper, et al.. (2000). Mutagen sensitivity in patients with familial and non-familial urothelial cell carcinoma. International Journal of Cancer. 88(3). 493–496. 7 indexed citations
12.
Koper, N.P., et al.. (1999). An illustration of the clinical relevance of detecting human antimouse antibody interference by affinity chromatography. European Journal of Obstetrics & Gynecology and Reproductive Biology. 86(2). 203–205. 5 indexed citations
13.
Koper, N.P., Leon F.A.G. Massuger, Chris M.G. Thomas, Lambertus A. Kiemeney, & André L. M. Verbeek. (1998). Serum CA 125 measurements to identify patients with endometrial cancer who require lymphadenectomy.. PubMed. 18(3B). 1897–902. 27 indexed citations
14.
Koper, N.P., et al.. (1998). Quantitation of IgG and IgM Human Anti-Mouse Antibodies (HAMA) Interference in CA 125 Measurements Using Affinity Chromatography. Clinical Chemistry and Laboratory Medicine (CCLM). 36(1). 23–28. 7 indexed citations
15.
Massuger, Leon F.A.G., et al.. (1997). Improvement of Clinical Staging in Cervical Cancer with Serum Squamous Cell Carcinoma Antigen and CA 125 Determinations. Gynecologic Oncology. 64(3). 473–476. 29 indexed citations
16.
Koper, N.P., Chris M.G. Thomas, L.F.A.G. Massuger, et al.. (1997). Serum CA 125 concentrations in women of different ages, hormonal statuses, orclinical conditions. International Journal of Gynecological Cancer. 7(5). 405–411. 4 indexed citations
17.
Koper, N.P., Chris M.G. Thomas, Leon F.A.G. Massuger, et al.. (1997). Comparison of four 'second generation' immunoassay systems to determine CA 125 in serum by using a graphical approach to method comparison analysis.. PubMed. 35(8). 617–23. 5 indexed citations
18.
Koper, N.P., et al.. (1996). Ovarian cancer incidence (1989–1991) and mortality (1954–1993) in the Netherlands. Obstetrics and Gynecology. 88(3). 387–393. 24 indexed citations
19.
Kiemeney, Lambertus A., J.W.W. Coebergh, N.P. Koper, et al.. (1994). Bladder cancer incidence and survival in the south-eastern part of the Netherlands, 1975–1989. European Journal of Cancer. 30(8). 1134–1137. 37 indexed citations
20.
Kiemeney, Lambertus A., et al.. (1994). Should random urothelial biopsies be taken from patients with primary superficial bladder cancer? A decision analysis. British Journal of Urology. 73(2). 164–171. 76 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Soon‐Beom Kang Breakdown of academic impact, for papers by Hamdy A. Azim Breakdown of academic impact, for papers by Sileny Han Breakdown of academic impact, for papers by Catherine Shannon Breakdown of academic impact, for papers by J. F. Pringle Breakdown of academic impact, for papers by Jørn Andersen Breakdown of academic impact, for papers by Noriko Seki Breakdown of academic impact, for papers by Josep R. Germà Breakdown of academic impact, for papers by Robert D. Legare Breakdown of academic impact, for papers by Jeffrey Schneider
Rankless by CCL
2026